人彌漫性大B細(xì)胞淋巴瘤細(xì)胞DoHH2

簡要描述：青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！

更新時間：2021-05-25

廠商性質(zhì)：生產(chǎn)廠家

瀏覽次數(shù)：332

留言詢價聯(lián)系我們

詳情介紹

品牌	其他品牌	貨號	BFN60808592
規(guī)格	T25培養(yǎng)瓶x1 1.5ml凍存管x2	供貨周期	現(xiàn)貨
主要用途	僅供科研	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)

細(xì)胞名稱	人彌漫性大B細(xì)胞淋巴瘤細(xì)胞DoHH2
貨物編碼	BFN60808592
產(chǎn)品規(guī)格	T25培養(yǎng)瓶x1	1.5ml凍存管x2
細(xì)胞數(shù)量	1x10^6	1x10^6
保存溫度	37℃	-198℃
運輸方式	常溫保溫運輸	干冰運輸
安全等級	1
用途限制	僅供科研 3類

培養(yǎng)體系	DMEM高糖培養(yǎng)基+10%FBS+1%三抗
培養(yǎng)溫度	37℃	二氧化碳濃度	5%
簡介	人彌漫性大B細(xì)胞淋巴瘤細(xì)胞DoHH2取自60歲男性，該細(xì)胞源于DSMZ
注釋	Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: LL-100 blood cancer cell line panel. Part of: MD Anderson Cell Lines Project. Part of: TCGA-110-CL cell line panel. Doubling time: 48 hours, in RPMI 1640 + 5% FBS (PubMed=1849602); ~40 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV). Omics: Array-based CGH. Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Genome sequenced. Omics: H3K9ac ChIP-seq epigenome analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. Omics: Virome analysis using RNAseq. Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type. Derived from sampling site: Pleural effusion.
基因突變
HLA信息	Class I HLA-A *A01:01,01:01 HLA-B B08:01,44:02* HLA-C *C07:04,07:04 Class II HLA-DQ DQA101:02,01:02* *DQB105:01,06:02 HLA-DR DRB115:01,01:01*
STR信息	Amelogenin X,Y CSF1PO 11,12 D3S1358 15,17 D5S818 11,12 D7S820 11 D8S1179 13,16 D13S317 12,13 D16S539 11,14 D18S51 11,14 D21S11 30 FGA 21,27 Penta D 9,12 Penta E 12,16 TH01 9 TPOX 8,11 vWA 14,19
參考文獻(xiàn)	PubMed=30285677; DOI=10.1186/s12885-018-4840-5 Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P. Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines. BMC Cancer 18:940-940(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019) PubMed=31395879; DOI=10.1038/s41467-019-11415-2 Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat. Commun. 10:3574-3574(2019)

青旗（上海）生物技術(shù)發(fā)展有限公司，總部位于上海浦東新區(qū)，依托本地高校資源，逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn)、培訓(xùn)為一體的綜合化產(chǎn)業(yè)平臺，在標(biāo)準(zhǔn)化細(xì)胞庫建立及細(xì)胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細(xì)胞、細(xì)胞系、ELISA試劑盒、感受態(tài)細(xì)胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負(fù)責(zé)的態(tài)度，以對科研的高度嚴(yán)謹(jǐn)，以嚴(yán)格的質(zhì)量控制，為廣大生物醫(yī)學(xué)科研用戶提供更優(yōu)質(zhì)的服務(wù)！